Saturday 17 October 2026 Export RARE’s income statement to Excel — free account

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

14.54 0.63 −4.15%

Follow RARE

Alert me

Market cap: $1.5B
P/E: 0.0×
Fwd P/E: −4.8×
Dividend yield: —
F-score: 5/9
Altman Z: −3.57
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.70

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	1	1	8	1	3	3	1	2	2	—

Insider Ownership 11.49%

Capital & Financial Ratios $m

Market Cap 1,500.00

Revenue 717.00

Net Income (586.00)

Free Cash Flow (494.00)

Net Debt (292.00)

Current Ratio 1.73

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (4.84)

P/S ratio 2.07

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 21.03%

Next Y EPS Growth 85.10%

Next Y revenue growth 13.16%

Next 5Y EPS Growth 71.02%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.57%

10-year low 10-year high

EV/Sales against its own 10 years 0.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	577	610	680	292
Receivables	73	122	158	200
Inventory	34	45	52	59
Other	—	—	—	—
	732	817	951	606

	2023	2024	2025	Q'26
Payables	42	39	31	39
ST’ Debt	—	—	—	—
Other	29	54	76	91
	280	344	384	351

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.95%	22.81%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	136	214	—	—	—
’25	139	167	160	207	673
’24	109	147	139	165	560
’23	100	108	98	127	434
’22	80	89	91	103	363
’21	99	87	82	83	351
’20	36	62	81	92	271

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(197)	(97)	—	—	—
’25	(166)	(109)	(91)	(100)	(466)
’24	(191)	(77)	(67)	(79)	(414)
’23	(157)	(116)	(118)	(84)	(475)
’22	(118)	(77)	(95)	(90)	(380)
’21	(159)	(65)	(60)	(54)	(339)
’20	(95)	87	(62)	(62)	(132)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(203)	(98)	—	—	—
’25	(182)	(112)	(92)	(101)	(487)
’24	(204)	(81)	(69)	(80)	(434)
’23	(182)	(133)	(122)	(86)	(522)
’22	(180)	(108)	(121)	(117)	(527)
’21	(176)	(85)	(80)	(70)	(412)
’20	(109)	83	(66)	(84)	(176)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.84)	(0.90)	—	—	—
’25	(1.57)	(1.17)	(1.81)	(1.29)	(5.83)
’24	(2.03)	(1.52)	(1.40)	(1.39)	(6.29)
’23	(2.33)	(2.25)	(2.23)	(1.52)	(8.25)
’22	(2.19)	(2.26)	(3.50)	(2.16)	(10.12)
’21	(2.03)	(1.81)	(1.08)	(1.79)	(6.70)
’20	(2.05)	0.41	(1.13)	(0.37)	(3.07)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	46.52	43.14	37.44	35.41	31.99	72.89	33.36	31.52	37.02	18.41	Analyst estimates 2026–2028 Powerpack
	High	110.06	91.35	90.98	74.50	179.65	175.00	88.12	54.98	60.37	46.50
People
People	Employees	376	520	610	740	893	1,119	1,311	1,276	1,294	1,371
	Revenue/emp, $m	0.00	0.01	0.08	0.14	0.30	0.31	0.28	0.34	0.43	0.49
Income, $m
Income, $m	Revenue	0	3	51	104	271	351	363	434	560	673
	Gross margin, %	100.00	99.96	97.77	91.31	97.74	95.44	92.21	89.63	86.25	83.80
	EBT	(246)	(318)	(197)	(399)	(185)	(453)	(702)	(609)	(567)	(571)
	EBT margin, %	(184,841.35)	(12,187.52)	(382.75)	(385.14)	(68.39)	(128.91)	(193.14)	(140.32)	(101.25)	(84.84)
	Net income	(246)	(302)	(198)	(403)	(187)	(454)	(707)	(607)	(569)	(575)
	Depreciation	8	8	17	2	13	20	21	13	23	31
Per share, $
Per share, $	Revenue	0.00	0.06	1.03	1.83	4.45	5.18	5.20	5.90	6.19	6.83
	Earnings	(6.21)	(7.12)	(3.97)	(7.12)	(3.07)	(6.70)	(10.12)	(8.25)	(6.29)	(5.83)
	Cash flow	(4.07)	(5.98)	(5.84)	(6.10)	(2.17)	(5.00)	(5.44)	(6.46)	(4.57)	(4.73)
	Capex	(0.26)	(0.07)	(0.08)	(0.44)	(0.72)	(1.08)	(2.09)	(0.64)	(0.22)	(0.21)
	Free cash flow	(4.32)	(6.05)	(5.92)	(6.54)	(2.89)	(6.07)	(7.53)	(7.10)	(4.80)	(4.94)
	Book value	11.97	9.03	12.23	11.56	18.97	13.61	5.04	3.75	2.82	(0.81)
	Shares, m	40	42	50	57	61	68	70	74	91	99
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	767.05	42.03	23.30	31.08	16.22	8.76	8.16	6.80	3.37
	P/B	5.84	5.46	3.55	3.70	7.30	6.18	9.03	12.86	14.93	0.00
	EV/Sales	0.00	681.09	33.10	16.02	26.64	14.12	6.70	6.83	5.71	2.36
	EV/FCF	(13.95)	(7.24)	(5.78)	(4.49)	(41.00)	(12.05)	(4.62)	(5.68)	(7.37)	(3.26)
Cash, $m
Cash, $m	Operating cash flow	(161)	(254)	(291)	(345)	(132)	(339)	(380)	(475)	(414)	(466)
	Capex	(10)	(3)	(4)	(25)	(44)	(73)	(146)	(47)	(20)	(21)
	Free cash flow	(171)	(257)	(295)	(370)	(176)	(412)	(527)	(522)	(434)	(487)
Balance, $m
Balance, $m	Working capital	341	199	448	748	1,106	675	623	452	473	567
	Total debt	—	—	—	352	384	394	907	—	—	—
	Net debt	(382)	(234)	(460)	(755)	(1,202)	(740)	(748)	(577)	(610)	(680)
	Shareholders’ equity	474	383	609	654	1,154	923	352	275	255	(80)
Returns, %
Returns, %	ROA	(44.70)	(58.59)	(32.65)	(43.42)	(12.89)	(27.67)	(46.12)	(39.98)	(38.01)	(37.89)
	ROIC	(167.73)	(138.02)	(155.57)	0.00	0.00	(130.83)	0.00	0.00	0.00	0.00
	ROE	(48.93)	(70.48)	(39.83)	(63.79)	(20.64)	(43.72)	(110.96)	(193.34)	(214.55)	(657.14)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GPCR Structure Therapeutics Inc. Sponsored ADR	$1.6B	— (loss-making)	—	—	n/m	−119.15% (below 0%: shrinking)	0.00%	0.00%	Compare
QURE uniQure N.V.	$1.6B	— (loss-making)	— (loss-making)	+11.00% (above 0%: growing)	n/m	+27.66% (above 0%: growing)	94.01%	(893.73%)	Compare
KRSA Korsana Biosciences, Inc.	$1.5B	— (loss-making)	— (loss-making)	−43.24% (below 0%: shrinking)	n/m	−184.69% (below 0%: shrinking)	100.00%	0.00%	Compare
MAZE Maze Therapeutics, Inc.	$1.5B	— (loss-making)	—	—	n/m	+50.21% (above 0%: growing)	100.00%	0.00%	Compare
ABSI Absci Corporation	$1.5B	— (loss-making)	— (loss-making)	−46.37% (below 0%: shrinking)	n/m	−71.74% (below 0%: shrinking)	100.00%	(10,741.51%)	Compare
IMCR Immunocore Holdings PLC Sponsored ADR	$1.5B	— (loss-making)	208×	+18.34% (above 0%: growing)	n/m	−40.74% (below 0%: shrinking)	99.06%	(2.58%)	Compare
RARE Ultragenyx Pharmaceutical Inc.	$1.5B	— (loss-making)	— (loss-making)	+28.14% (above 0%: growing)	n/m	+12.50% (above 0%: growing)	84.11%	(35.05%)
ANAB AnaptysBio, Inc.	$1.5B	— (loss-making)	220×	−7.98% (below 0%: shrinking)	n/m	−141.60% (below 0%: shrinking)	100.00%	(135.53%)	Compare
RAPP Rapport Therapeutics, Inc.	$1.4B	— (loss-making)	—	—	n/m	−64.75% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.5B	—	—	−7.98%	—	−68.24%	100.00%	(1.29%)

All 614 Biotechnology stocks →

Ultragenyx Pharmaceutical Inc. (RARE) key facts

Concern: Ultragenyx Pharmaceutical Inc. reported a net loss of $575.0 million, or a loss of $5.83 per share, for fiscal 2025.
Strength: Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024.
Ultragenyx Pharmaceutical Inc. (RARE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RARE traded at $14.54, a market capitalization of $1.5 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.1× sales.
Return on equity was −657.1% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −3.57 (distress zone) for fiscal 2025.